Compare EVTL & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | ABEO |
|---|---|---|
| Founded | 2016 | 1974 |
| Country | United Kingdom | United States |
| Employees | 454 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.7M | 307.5M |
| IPO Year | N/A | 2005 |
| Metric | EVTL | ABEO |
|---|---|---|
| Price | $2.16 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $12.70 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.0M |
| Earning Date | 03-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.90 | $4.00 |
| 52 Week High | $7.60 | $7.54 |
| Indicator | EVTL | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 46.84 |
| Support Level | $1.90 | $5.20 |
| Resistance Level | $2.89 | $5.54 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 2.68 | 39.88 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.